Structure-Based Design, Synthesis by Click Chemistry and in Vivo Activity of Highly Selective A3 Adenosine Receptor Agonists.

2-Arylethynyl derivatives of (N)-methanocarba adenosine 5'-uronamides are selective A3AR (adenosine receptor) agonists. Here we substitute a 1,2,3-triazol-1-yl linker in place of the rigid, linear ethynyl group to eliminate its potential metabolic liability. Docking of nucleosides containing possible short linker moieties at the adenine C2 position using a hybrid molecular model of the A3AR (based on the A2AAR agonist-bound structure) correctly predicted that a triazole would maintain the A3AR selectivity, due to its ability to fit a narrow cleft in the receptor. The analogues with various N6 and C2-aryltriazolyl substitution were synthesized and characterized in binding (Ki at hA3AR 0.3 - 12 nM) and in vivo to demonstrate efficacy in controlling chronic neuropathic pain (chronic constriction injury). Among N6-methyl derivatives, a terminal pyrimidin-2-yl group in 9 (MRS7116) increased duration of action (36% pain protection at 3 h) in vivo. N6-Ethyl 5-chlorothien-2-yl analogue 15 (MRS7126) preserved in vivo efficacy (85% protection at 1 h) with short duration. Larger N6 groups, e.g. 17 (MRS7138, >90% protection at 1 and 3 h), greatly enhanced in vivo activity. Thus, we have combined structure-based methods and phenotypic screening to identify nucleoside derivatives having translational potential.

[1]  C. Nájera,et al.  The Sonogashira reaction: a booming methodology in synthetic organic chemistry. , 2007, Chemical reviews.

[2]  K. Jacobson,et al.  Methanocarba ring as a ribose modification in ligands of G protein-coupled purine and pyrimidine receptors: synthetic approaches. , 2013, MedChemComm.

[3]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[4]  Francesca Deflorian,et al.  Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. , 2012, Journal of medicinal chemistry.

[5]  Gary J. Bennett,et al.  A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man , 1988, Pain.

[6]  K. Varani,et al.  The A3 Adenosine Receptor: History and Perspectives , 2015, Pharmacological Reviews.

[7]  Kenneth A Jacobson,et al.  Controlling murine and rat chronic pain through A3 adenosine receptor activation , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  K. Jacobson,et al.  2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists. , 2010, Bioorganic & medicinal chemistry.

[9]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[10]  M. G. Finn,et al.  Click Chemistry: Diverse Chemical Function from a Few Good Reactions. , 2001, Angewandte Chemie.

[11]  K. Jacobson,et al.  Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. , 2000, Journal of medicinal chemistry.

[12]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[13]  Silvia Paoletta,et al.  Structural Probing of Off-Target G Protein-Coupled Receptor Activities within a Series of Adenosine/Adenine Congeners , 2014, PloS one.

[14]  Silvia Paoletta,et al.  Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. , 2013, Journal of medicinal chemistry.

[15]  Steven M. Moss,et al.  In Vivo Phenotypic Screening for Treating Chronic Neuropathic Pain: Modification of C2-Arylethynyl Group of Conformationally Constrained A3 Adenosine Receptor Agonists , 2014, Journal of medicinal chemistry.

[16]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[17]  K. Jacobson,et al.  Synthesis of Ethyl (1S,2R,3S,4S,5S)-2,3-O-(Isopropylidene)-4-Hydroxy-Bicyclo[3.1.0]Hexane-Carboxylate from L-Ribose: A Versatile Chiral Synthon for Preparation of Adenosine and P2 Receptor Ligands , 2008, Nucleosides, nucleotides & nucleic acids.

[18]  V. Strand,et al.  Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. , 2008, The Journal of rheumatology.

[19]  Francesca Deflorian,et al.  High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks , 2013, In Silico Pharmacology.

[20]  P. Fishman,et al.  The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. , 2008, International journal of oncology.

[21]  K. Jacobson,et al.  2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. , 2006, Journal of medicinal chemistry.

[22]  K. Jacobson,et al.  Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. , 2008, Bioorganic & medicinal chemistry letters.

[23]  P. Edwards,et al.  Managing the liabilities arising from structural alerts: a safe philosophy for medicinal chemists. , 2011, Current medicinal chemistry.

[24]  K. Jacobson,et al.  Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. , 2015, Brain : a journal of neurology.